ストックスクリーナーアプリを入手
104.97
0.33%
0.35
プレマーケット:
104.47
-0.50
-0.48%
前日終値:
$104.62
開ける：
$104.24
24時間の取引高:
105.13K
Relative Volume:
0.97
時価総額：
$2.05B
収益：
$152.42M
当期純損益:
$45.24M
株価収益率:
41.82
EPS:
2.51
ネットキャッシュフロー:
$6.97M
1週間 パフォーマンス:
+3.63%
1か月 パフォーマンス:
-4.53%
6か月 パフォーマンス:
-0.87%
1年 パフォーマンス:
+33.09%
1日の値動き範囲:
$101.24
$106.00
1週間の範囲:
$100.30
$107.61
52週間の値動き範囲:
$67.72
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
名前
Ligand Pharmaceuticals Inc
セクター
電話
858-550-7500
住所
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
104.97 | 2.05B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Stifel | Buy |
| 2024-10-03 | 開始されました | Oppenheimer | Outperform |
| 2024-07-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 再開されました | Stephens | Overweight |
| 2021-02-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-06 | 開始されました | Barclays | Overweight |
| 2020-03-24 | ダウングレード | Argus | Buy → Hold |
| 2020-03-10 | 開始されました | Guggenheim | Neutral |
| 2020-02-06 | 開始されました | The Benchmark Company | Buy |
| 2019-09-19 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-10-29 | アップグレード | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-11 | 繰り返されました | Argus | Buy |
| 2018-08-17 | 開始されました | Goldman | Neutral |
| 2018-08-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 開始されました | Argus | Buy |
| 2017-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-05 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-05 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 開始されました | Sidoti | Buy |
| 2016-03-03 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Revisiting Ligand Pharmaceuticals Stock, Accumulate If Shares Dip Below $100 (NASDAQ:LGND) - Seeking Alpha
Channel Therapeutics and Pelthos Therapeutics to Merge to Accelerate Launch of Zelsuvmi for Molluscum Contagiosum - Dermatology Times
Channel Therapeutics stock climbs on M&A deal (LGND:NASDAQ) - Seeking Alpha
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated - MSN
Channel Therapeutics Sees Major Gains After Pharma Merger News - Finimize
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated By Stocktwits - Investing.com India
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand, Channel Agree To Combine Pelthos, LNHC With CHRO Merger Sub - Nasdaq
Ligand Pharma Announces Merger to Enhance ZELSUVMI Sales - TipRanks
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics | LGND Stock News - GuruFocus
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire
Groundbreaking Skin Treatment Powers $50M Merger: First-Ever FDA-Approved Home Therapy for Molluscum - Stock Titan
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused EntityLigand Pharmaceuticals (NASDAQ:LGND), Channel Therapeutics (AMEX:CHRO) - Benzinga
Alliancebernstein L.P. Sells 1,460 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Upgraded at StockNews.com - Defense World
Wellington Management Group LLP Sells 1,085 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Stifel Nicolaus Initiates Coverage on Ligand Pharmaceuticals (NASDAQ:LGND) - Defense World
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy - Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Norges Bank Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Stifel Initiates Coverage of Ligand (LGND) with Positive Outlook - GuruFocus
Stifel starts Ligand Pharma stock with Buy, $143 target By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded by StockNews.com to Sell - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by American Century Companies Inc. - Defense World
Vanguard Group Inc. Buys 115,005 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
3,900 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Acquired by KLP Kapitalforvaltning AS - Defense World
Sei Investments Co. Purchases 677 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Short Interest Update - Defense World
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Teacher Retirement System of Texas Boosts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
HighTower Advisors LLC Boosts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Raymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Swiss National Bank Has $3.86 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand’s Second Quarter Financial Results to be Reported August 3rd - Business Wire
Victory Capital Management Inc. Buys 200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com - Defense World
US Bancorp DE Acquires 98 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Atria Investments Inc - Defense World
Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Smartleaf Asset Management LLC Buys 221 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus
Mutual of America Capital Management LLC Has $307,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
CFO’s Major Stock Sale Shakes Up Ligand Pharma - TipRanks
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock - Investing.com
Truist Financial Corp Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Ligand Pharmaceuticals Inc (LGND) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):